All In Biotech

Drug Trial Radar · NCT02385097

Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block

A Prospective, Randomised, Non-inferiority Study of Chloroprocaine 2% and the Active Control Ropivacaine 0.75% (AstraZeneca) in Ultrasound-guided Axillary Nerve Block for Short-duration Distal Upper Limb Surgery

Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 211 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

211

Actual

Start

Apr 2015

Primary completion

May 2017

Study completion May 2017

Sponsor

Lead sponsor
Sintetica SAIndustry
Sponsor type
Industry
Collaborators
Cross S.A.
First posted
Mar 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries Successful block: anaesthesia adequate for the surgery without any supplementation in the first 45 min.

Conditions

  • Axillary Nerve Block

Interventions

  • Chloroprocaine HCl 2%Drug

    Single Administration (20mL) by Axillary Nerve Route

  • Ropivacaine 0.75%Drug

    Single Administration (20mL) by Axillary Nerve Route

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Successful Block for Distal Upper Limb SurgeriesTime frame: 45 min from the time of readiness of surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Claudio Camponovo

    Gravesano, Lugano, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.